Intercept to Present at Upcoming Investor Conferences
February 19, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Linda Richardson as Chief Commercial Officer
February 17, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept...
Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Company Statement on Analyst Note
January 27, 2021 13:35 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
January 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Announces Leadership Transition
December 10, 2020 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Jerry Durso Appointed CEO Effective January 1, 2021;Founder, President and CEO Mark Pruzanski to Continue as Board Member and Advisor NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept...
Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH
November 16, 2020 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update
November 09, 2020 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to...